Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip
- PMID: 16271424
- DOI: 10.1016/j.vaccine.2005.10.008
Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip
Abstract
Safety data on the inactivated split influenza vaccine, Vaxigrip, were compiled and analysed from 28 clinical trials (total: 4599 subjects aged 6 months to 99 years) to provide a robust estimate of the reactogenicity profile. The most frequent solicited reactions were non-severe injection site pain and erythema in children, adults, and elderly. Mild or moderate fever was the most frequent reaction in 6-36 months olds; few systemic reactions were reported in older groups. Reactogenicity was comparable in healthy and high-risk children. The long-term experience with the world's most widely used influenza vaccine, Vaxigrip, confirms its excellent tolerability, and supports its continued use in clinical practice worldwide.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical